Mono Pharmacare share price & results
- Mar 2026
- Sept 2025
Ahmedabad-based pharmaceutical/healthcare company listed on NSE's SME Emerge platform, operating through a network of related-party pharma trading and distribution entities.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 99.0 | +22.2% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 2.2 | −1.4 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.00 | −100.0% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
| Return on equity | −6.9 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | 1.81 | +4.3 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | −38.9 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance −57.3% 1Y
1Y: ₹20.85 on 24 Oct 2025 → ₹8.9. High ₹22.05 (28 Nov 2025), low ₹7.6 (10 Aug 2026).
- Previous close
- ₹8.5
- Market cap
- ₹15 Cr
- 52-week range
- ₹7.6 – ₹22.05
- One year
- −57.62%
- Price to earnings (FY ending Mar 2026)
- 14.70×
- Return on equity (FY ending Mar 2026)
- 3.13%
Overview
- Symbol
- NSE:MONOPHARMA
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Mono Pharmacare Ltd does
Based on the company's own presentations, annual report and earnings calls.
Mono Pharmacare Limited is a healthcare-sector company headquartered in Ahmedabad, Gujarat, listed on the NSE SME Emerge platform under the symbol MONOPHARMA. Its operations are closely tied to a group of related entities — including Supal Pharma, Supal Pharmacare Ltd, Supal Medical & Wholesale LLP, Ahmedabad Medical Corporation, Supal Distributors LLP and Supal Trading LLC-Dubai — with which it carries out sale/purchase transactions of goods in the ordinary course of business. The company holds a 99% stake in two associate entities, Ahmedabad Medical Corporation and Supal Distributors LLP, which operate in the same line of business. Its FY25 annual report records nil energy-conservation, technology-absorption and foreign-exchange activity, consistent with a trading/distribution rather than manufacturing operating model.
- Associate/distribution entities
- 2 (99% stake each — Ahmedabad Medical Corporation, Supal Distributors LLP)
- Geographic footprint
- Domestic operations only — nil foreign exchange earnings/outgo in FY25
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 4 fiscal years held (Mar 2023 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −100% (quarter to mar 2026 against mar 2025).
| Line item | Mar 2023 | Sept 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 35 | 67 | 56 | 87 | 81 | 66 | 99 |
| Expenses | 33 | 63 | 53 | 82 | 78 | 65 | 97 |
| Operating profit | 2 | 4 | 2 | 5 | 3 | 2 | 2 |
| Operating margin | 6.0% | 6.0% | 4.4% | 5.0% | 3.6% | 2.7% | 2.2% |
| Other income | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 2 | 1 | 3 | 1 | 0 | 0 |
| Tax rate | 39.0% | 20.0% | 33.0% | 27.0% | 37.0% | 83.0% | 29.0% |
| Net profit | 1 | 2 | 1 | 2 | 1 | 0 | 0 |
| EPS (₹ per share) | 0.52 | 1.06 | 0.33 | 1.30 | 0.46 | 0.01 | 0.19 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 12 | 18 | 18 | 18 | 18 |
| Reserves | 1 | 10 | 14 | 14 | 14 |
| Borrowings | 40 | 41 | 54 | 55 | 56 |
| Other liabilities | 9 | 12 | 25 | 33 | 34 |
| Total liabilities | 63 | 81 | 110 | 119 | 122 |
| Fixed assets | 1 | 1 | 1 | 1 | 1 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 | 0 |
| Other assets | 61 | 80 | 109 | 118 | 121 |
| Total assets | 63 | 81 | 110 | 119 | 122 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Cash from operations | -40 | -9 | -4 |
| Cash from investing | -1 | 0 | 0 |
| Cash from financing | 41 | 8 | 5 |
| Net cash flow | 0 | 0 | 0 |
| Free cash flow | -40 | -9 | -5 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor days | 241 | 94 | 91 | 165 |
| Inventory days | 408 | 139 | 133 | 99 |
| Days payable | 87 | 32 | 45 | 68 |
| Cash conversion cycle | 563 | 202 | 179 | 196 |
| Working capital days | 299 | 131 | 120 | 126 |
| Return on capital employed | — | 10.0% | 11.0% | 5.0% |
| Dividend payout | — | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Promoters hold 56.72% as of Sept 2025.
- Promoters 56.72%
- Public 43.28%
Who bought this quarter
since Mar 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- +0.98 pp 2.29% held
- +0.19 pp 1.27% held
- +0.11 pp 1.63% held
- +0.09 pp 2.33% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Sep 2025 filing
Every holder of Mono Pharmacare Ltd above SEBI's 1% disclosure line, and what changed since Mar 2025.
| Holder | Stake | Change |
|---|---|---|
| 45.43% | unchanged | |
| 11.28% | unchanged | |
| 3.68% | unchanged | |
| 2.33% | +0.09 pp | |
| 2.29% | +0.98 pp | |
| 1.79% | unchanged | |
| 1.63% | +0.11 pp | |
| 1.28% | unchanged | |
| 1.27% | +0.19 pp | |
| 1.13% | unchanged | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Mono Pharmacare Ltd
Free account: one company. Everything above stays public.
Write why you follow Mono Pharmacare Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Mono Pharmacare Ltd
Guides on how to read this kind of business and the numbers that matter.